INARI MEDICAL INC (NARI)
US45332Y1091 - Common Stock
We assign a fundamental rating of 4 out of 10 to NARI. NARI was compared to 188 industry peers in the Health Care Equipment & Supplies industry. NARI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NARI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NARI had negative earnings in the past year.
NARI had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: NARI reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: NARI reported negative operating cash flow in multiple years.
1.2 Ratios
NARI has a Return On Assets of -11.27%. This is comparable to the rest of the industry: NARI outperforms 57.22% of its industry peers.
The Return On Equity of NARI (-18.07%) is better than 61.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.27% | ||
| ROE | -18.07% | ||
| ROIC | N/A |
ROA(3y)-0.97%
ROA(5y)0.17%
ROE(3y)-1.09%
ROE(5y)-0.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NARI (86.82%) is better than 97.33% of its industry peers.
NARI's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NARI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.99%
GM growth 5Y1.71%
2. Health
2.1 Basic Checks
NARI does not have a ROIC to compare to the WACC, probably because it is not profitable.
NARI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NARI has more shares outstanding
NARI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
NARI has an Altman-Z score of 7.21. This indicates that NARI is financially healthy and has little risk of bankruptcy at the moment.
NARI has a Altman-Z score of 7.21. This is amongst the best in the industry. NARI outperforms 84.49% of its industry peers.
There is no outstanding debt for NARI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.21 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
NARI has a Current Ratio of 1.77. This is a normal value and indicates that NARI is financially healthy and should not expect problems in meeting its short term obligations.
NARI has a Current ratio of 1.77. This is in the lower half of the industry: NARI underperforms 73.26% of its industry peers.
A Quick Ratio of 1.40 indicates that NARI should not have too much problems paying its short term obligations.
NARI has a worse Quick ratio (1.40) than 65.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.4 |
3. Growth
3.1 Past
NARI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1183.33%.
NARI shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.39%.
Measured over the past years, NARI shows a very strong growth in Revenue. The Revenue has been growing by 135.60% on average per year.
EPS 1Y (TTM)-1183.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y52.31%
Revenue growth 5Y135.6%
Sales Q2Q%21.39%
3.2 Future
NARI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 138.95% yearly.
NARI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.42% yearly.
EPS Next Y-2435.92%
EPS Next 2Y160%
EPS Next 3Y169.36%
EPS Next 5Y138.95%
Revenue Next Year22.22%
Revenue Next 2Y20.23%
Revenue Next 3Y19.19%
Revenue Next 5Y13.42%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NARI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 347.76 indicates a quite expensive valuation of NARI.
Based on the Price/Forward Earnings ratio, NARI is valued a bit cheaper than 65.24% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.00, NARI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 347.76 |
4.2 Price Multiples
NARI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. NARI is cheaper than 66.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1844.6 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NARI's earnings are expected to grow with 169.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y160%
EPS Next 3Y169.36%
5. Dividend
5.1 Amount
No dividends for NARI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INARI MEDICAL INC
NASDAQ:NARI (11/22/2024, 8:00:00 PM)
After market: 49.66 0 (0%)49.66
-0.09 (-0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.91B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 347.76 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.27% | ||
| ROE | -18.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.82% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.4 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1183.33%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-2435.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.39%
Revenue growth 3Y52.31%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y